Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

General Health

Other Science

Science

Injectable Aesthetics portfolio

More Like This

Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets

Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS